MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 206813 | Name: JPH203 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JPH203, also known as KYT-0353, is a potent and selective LAT1 selective ( L-type amino acid transporter 1) inhibitor. JPH203 can very potently inhibit l-leucine uptake. JPH203 inhibits YD-38 cell growth. JPH203 up-regulated the population of apoptotic YD-38 cells through the activation of apoptotic factors, including caspases and PARP. (note: As per requested by patent owner, JPH203 can only be used solely for the purpose of obtaining information to be submitted to the regulatory authorization for obtaining a marketing approval of JPH203).

Chemical Structure

JPH203 HCl
JPH203 HCl
CAS#1597402-27-1 (2HCl)

Theoretical Analysis

MedKoo Cat#: 206813

Name: JPH203 HCl

CAS#: 1597402-27-1 (2HCl)

Chemical Formula: C23H21Cl4N3O4

Exact Mass: 0.0000

Molecular Weight: 545.24

Elemental Analysis: C, 50.67; H, 3.88; Cl, 26.01; N, 7.71; O, 11.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1597402-27-1 (2HCl) 1037592-40-7 (free base) 1597402-28-2 (complex with beta cyclodextrin)
Synonym
JPH203 Dihydrochloride; 1597402-27-1; Nanvuranlat dihydrochloride; ZJK9MX8G8Q; JPH203 2HCl
IUPAC/Chemical Name
(S)-2-amino-3-(4-((5-amino-2-phenylbenzo[d]oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acid dihydrochloride
InChi Key
MJSAOPNUSNNYQL-NTEVMMBTSA-N
InChi Code
InChI=1S/C23H19Cl2N3O4.2ClH/c24-16-6-12(8-18(27)23(29)30)7-17(25)21(16)31-11-14-9-15(26)10-19-20(14)32-22(28-19)13-4-2-1-3-5-13;;/h1-7,9-10,18H,8,11,26-27H2,(H,29,30);2*1H/t18-;;/m0../s1
SMILES Code
O=C(O)[C@@H](N)CC1=CC(Cl)=C(OCC2=C(OC(C3=CC=CC=C3)=N4)C4=CC(N)=C2)C(Cl)=C1.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The intellectual property of JPH203 belongs to J-Pharma and Dr. Hitoshi Endou. The related patents are JP4705756, EP1481965, ZL03803549, KR100948278, AU2003208105, CA2475435, US7345068. This product is not sold to customers in Japan, UK, France, Germany, Switzerland, China, South Korea, Australia and Canada. In the United States, customer may buy this product only if the customer is engaged in IND (Investigational New Drug application) or NDA (New Drug Application) for obtaining a marketing approval of JPH203.
Product Data
Product Data
Instruction
View handling instruction
Biological target:
JPH203, also known as KYT-0353, is a potent and selective LAT1 selective ( L-type amino acid transporter 1) inhibitor.
In vitro activity:
The specific inhibition of LAT1 with JPH203 decreased LS174T proliferation by 60% (Fig. 3A and B, left). Consistent with the results for mTORC1 and GCN2 activity, LS174T-CD98KOand A549-CD98KD cells were able to maintain their proliferation at the same level as WT cells (Fig. 3A and B and Supplementary Fig. S3C). Furthermore, it was confirmed that this LAT1KO-specific antiproliferative effect (70% reduction) was observed in 3D culture assays (Fig. 3C). These findings demonstrate the essential role of LAT1 for maintenance of tumor cell AA homeostasis and proliferation. Reference: Cancer Res. 2016 Aug 1;76(15):4481-92. https://cancerres.aacrjournals.org/content/76/15/4481.long
In vivo activity:
Thyroid tumorigenesis was induced in 6-weeks old adult BrafCA/+;Pik3caLat/+;Thyro::CreERT2 mice by tamoxifen injection, which results in thyrocyte-specific expression of BRAFV600E and PIK3CAH1047R. A cohort of 12 mice was separated into two groups that were treated with either vehicle or 50 mg/kg JPH203 i.p. daily for five days per week during 6.5 weeks (Fig. 5a). Weekly ultrasound imaging revealed that JPH203 exerted an arrest of tumor growth already after 14 days of treatment, whereas tumors of vehicle-treated mice continued to grow until the end of the experiment (Fig. 5c). This data shows that LAT1 plays a critical role in tumor growth in mice, suggesting that LAT1 helps cells grow in the physiological environment that is low in amino acids. Reference: J Exp Clin Cancer Res. 2018 Sep 21;37(1):234. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150977/
Solvent mg/mL mM
Solubility
DMSO 54.5 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 545.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y, Endou H. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010 Jan;101(1):173-9. doi: 10.1111/j.1349-7006.2009.01386.x. Epub 2009 Oct 8. PMID: 19900191. 2. Cormerais Y, Giuliano S, LeFloch R, Front B, Durivault J, Tambutté E, Massard PA, de la Ballina LR, Endou H, Wempe MF, Palacin M, Parks SK, Pouyssegur J. Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. Cancer Res. 2016 Aug 1;76(15):4481-92. doi: 10.1158/0008-5472.CAN-15-3376. Epub 2016 Jun 14. Erratum in: Cancer Res. 2017 Jul 1;77(13):3721. PMID: 27302165. 3. Häfliger P, Graff J, Rubin M, Stooss A, Dettmer MS, Altmann KH, Gertsch J, Charles RP. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. J Exp Clin Cancer Res. 2018 Sep 21;37(1):234. doi: 10.1186/s13046-018-0907-z. PMID: 30241549; PMCID: PMC6150977.
In vitro protocol:
1. Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y, Endou H. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010 Jan;101(1):173-9. doi: 10.1111/j.1349-7006.2009.01386.x. Epub 2009 Oct 8. PMID: 19900191. 2. Cormerais Y, Giuliano S, LeFloch R, Front B, Durivault J, Tambutté E, Massard PA, de la Ballina LR, Endou H, Wempe MF, Palacin M, Parks SK, Pouyssegur J. Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. Cancer Res. 2016 Aug 1;76(15):4481-92. doi: 10.1158/0008-5472.CAN-15-3376. Epub 2016 Jun 14. Erratum in: Cancer Res. 2017 Jul 1;77(13):3721. PMID: 27302165.
In vivo protocol:
1. Häfliger P, Graff J, Rubin M, Stooss A, Dettmer MS, Altmann KH, Gertsch J, Charles RP. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. J Exp Clin Cancer Res. 2018 Sep 21;37(1):234. doi: 10.1186/s13046-018-0907-z. PMID: 30241549; PMCID: PMC6150977.
1: Otsuki H, Kimura T, Yamaga T, Kosaka T, Suehiro JI, Sakurai H. Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters. Prostate. 2016 Oct 3. doi: 10.1002/pros.23263. [Epub ahead of print] PubMed PMID: 27696482. 2: Cormerais Y, Giuliano S, LeFloch R, Front B, Durivault J, Tambutté E, Massard PA, de la Ballina LR, Endou H, Wempe MF, Palacin M, Parks SK, Pouyssegur J. Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. Cancer Res. 2016 Aug 1;76(15):4481-92. doi: 10.1158/0008-5472.CAN-15-3376. PubMed PMID: 27302165. 3: Ueno S, Kimura T, Yamaga T, Kawada A, Ochiai T, Endou H, Sakurai H. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor. J Pharmacol Sci. 2016 Jun;131(2):110-7. doi: 10.1016/j.jphs.2016.04.021. PubMed PMID: 27262901. 4: Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J, Hagenbeek T, Spits H, Reverso J, Ambrosetti D, Michiels JF, Bailly-Maitre B, Endou H, Wempe MF, Peyron JF. L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia. 2015 Jun;29(6):1253-66. doi: 10.1038/leu.2014.338. PubMed PMID: 25482130. 5: Yun DW, Lee SA, Park MG, Kim JS, Yu SK, Park MR, Kim SG, Oh JS, Kim CS, Kim HJ, Kim JS, Chun HS, Kanai Y, Endou H, Wempe MF, Kim DK. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells. J Pharmacol Sci. 2014;124(2):208-17. PubMed PMID: 24492461. 6: Toyoshima J, Kusuhara H, Wempe MF, Endou H, Sugiyama Y. Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203. J Pharm Sci. 2013 Sep;102(9):3228-38. doi: 10.1002/jps.23601. PubMed PMID: 23712732. 7: Wempe MF, Rice PJ, Lightner JW, Jutabha P, Hayashi M, Anzai N, Wakui S, Kusuhara H, Sugiyama Y, Endou H. Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound. Drug Metab Pharmacokinet. 2012;27(1):155-61. PubMed PMID: 21914964. 8: Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y, Endou H. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010 Jan;101(1):173-9. doi: 10.1111/j.1349-7006.2009.01386.x. PubMed PMID: 19900191.